SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000926617-23-000097
Filing Date
2023-12-06
Accepted
2023-12-06 16:43:48
Documents
14
Period of Report
2023-12-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20231206x8k.htm   iXBRL 8-K 73150
2 EX-99.1 awh-20231206xex99_1.htm EX-99.1 25160
3 GRAPHIC awh-20231206xex99_1g001.jpg GRAPHIC 4677
  Complete submission text file 0000926617-23-000097.txt   236044

Data Files

Seq Description Document Type Size
4 EX-101.SCH awh-20231206.xsd EX-101.SCH 2550
5 EX-101.LAB awh-20231206_lab.xml EX-101.LAB 15612
6 EX-101.PRE awh-20231206_pre.xml EX-101.PRE 11194
8 EXTRACTED XBRL INSTANCE DOCUMENT awh-20231206x8k_htm.xml XML 5016
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 231470159
SIC: 2835 In Vitro & In Vivo Diagnostic Substances